Solutions and aerosols of metal-containing compounds

• US 7,078,060 B2
• Filed: 02/12/2003
• Issued: 07/18/2006
• Est. Priority Date: 07/27/2000
• Status: Expired due to Term

• Current Assignee: NUCRYST Pharmaceuticals Corp. (The Westaim Corporation)
• Original Assignee: NUCRYST Pharmaceuticals Corp. (The Westaim Corporation)
• Inventors: Naylor, Antony G., Moxham, Peter H., Yin, Hua Qing, Lam, Kan, Wright, John B., Gillis, Scott H., Schechter, Paul, Burrell, Robert E.
• Primary Examiner(s): PAK, JOHN D
• Application Number:
  US10/364,983
• Publication Number:
  US 20030203046A1
• Time in Patent Office: 1,252 Days
• Field of Search: 424/489, 424618-619, 424/450, 514/275, 514/495, 514/184, 514/772, 514/858, 514/859, 514/865, 514/886, 514/887, 514/936, 514/937, 514/938, 514/946, 514/964
• US Class Current: 424/618
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 2800/413 Nanosized, i.e. having sizes below 100 nm
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/242 Gold; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 33/38 Silver; Compounds thereof
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 8/19 containing inorganic ingredients
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0078 for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/1682 Processes
• CPC Class Codes: A61K 9/51 Nanocapsules; Nanoparticles; nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61K 9/7023 Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61L 15/46 : Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
• CPC Class Codes: A61L 17/145 : Coating
• CPC Class Codes: A61L 2300/104 : Silver, e.g. silver sulfadiazine
• CPC Class Codes: A61L 2300/404 : Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/606 : Coatings
• CPC Class Codes: A61L 2300/63 : Crystals
• CPC Class Codes: A61L 27/30 : Inorganic materials
• CPC Class Codes: A61L 29/10 : Inorganic materials
• CPC Class Codes: A61L 31/082 : Inorganic materials
• CPC Class Codes: A61P 17/00 : Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 : for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61Q 17/005 : Antimicrobial preparations
• CPC Class Codes: A61Q 19/00 : Preparations for care of the skin
• CPC Class Codes: B82Y 5/00 : Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Solutions and aerosols of metal-containing compounds are disclosed. Methods of preparing and using the solutions and aerosols, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.

Claims

1. A pharmaceutical composition, comprising:

a pharmaceutically acceptable carrier selected from the group consisting of DMSO and liposomes; and

a silver-containing compound in the pharmaceutically acceptable carrier;

wherein;

the pharmaceutical composition comprises from about 0.01 weight percent to about 5 weight percent of the silver-containing compound;

when said pharmaceutically acceptable carrier is DMSO, DMSO is present in an amount sufficient to assist in the penetration of skin and the silver-containing compound is selected from the group consisting of nanocrystalline silver-containing compounds and atomically disordered silver-containing compounds; and

when said pharmaceutically acceptable carrier is a liposome, the silver-containing compound is selected from the group consisting of atomically disordered silver-containing compounds.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least about 0.1 weight percent of the silver-containing compound.

3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least about 0.5 weight percent of the silver-containing compound.

4. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least about 0.75 weight percent of the silver-containing compound.

5. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least about one weight percent of the silver-containing compound.

6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises at least about two weight percent of the silver-containing compound.

7. The pharmaceutical composition of claim 1, wherein the silver-containing compound is selected from the group consisting of atomically disordered silver oxides, silver nitrides, silver borides, silver halides and silver hydrides.

8. The pharmaceutical composition of claim 1, wherein the silver-containing compound is selected from the group consisting of atomically disordered silver oxides.

9. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound is selected from the group consisting of nanocrystalline silver oxides, silver nitrides, silver borides, silver halides and silver hydrides.

10. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound is selected from the group consisting of nanocrystalline silver oxides.

11. The pharmaceutical composition of claim 1, wherein the silver-containing compound is nanocrystalline silver and the pharmaceutically acceptable carrier is DMSO.

12. The pharmaceutical composition of claim 1, wherein the silver-containing compound is a nanocrystalline silver oxide and the pharmaceutically acceptable carrier is DMSO.

13. The pharmaceutical composition of claim 1, wherein the silver-containing compound is atomically disordered silver.

14. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is a liposome.

15. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of a sustained release article.

16. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound present in the composition is at least about 0.1 weight percent nanocrystalline silver.

17. The pharmaceutical composition of claim 16, wherein the silver-containing compound present in the composition is at least about 0.5 weight percent.

18. The pharmaceutical composition of claim 16, wherein the silver-containing compound present in the composition is at least about 0.75 weight percent.

19. The pharmaceutical composition of claim 16, wherein the silver-containing compound present in the composition is at least about 1 weight percent.

20. The pharmaceutical composition of claim 16, wherein the silver-containing compound present in the composition is at least about 2 weight percent.

21. The pharmaceutical composition of claim 1, wherein the silver-containing compound present in the composition is at least about 0.1 weight percent atomically disordered silver.

22. The pharmaceutical composition of claim 21, wherein the silver-containing compound present in the composition is at least about 0.5 weight percent.

23. The pharmaceutical composition of claim 21, wherein the silver-containing compound present in the composition is at least about 0.75 weight percent.

24. The pharmaceutical composition of claim 21, wherein the silver-containing compound present in the composition is at least about 1 weight percent.

25. The pharmaceutical composition of claim 21, wherein the silver-containing compound present in the composition is at least about 2 weight percent.

26. The pharmaceutical composition of claim 1, wherein the silver-containing compound present in the composition is at least about 0.1 weight percent atomically disordered silver oxide.

27. The pharmaceutical composition of claim 26, wherein the silver-containing compound present in the composition is at least about 0.5 weight percent.

28. The pharmaceutical composition of claim 26, wherein the silver-containing compound present in the composition is at least about 0.75 weight percent.

29. The pharmaceutical composition of claim 26, wherein the silver-containing compound present in the composition is at least about 1 weight percent.

30. The pharmaceutical composition of claim 26, wherein the silver-containing compound present in the composition is at least about 2 weight percent.

31. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound present in the composition is at least about 0.1 weight percent of a nanocrystalline silver oxide.

32. The pharmaceutical composition of claim 31, wherein the silver-containing compound present in the composition is at least about 0.5 weight percent.

33. The pharmaceutical composition of claim 31, wherein the silver-containing compound present in the composition is at least about 0.75 weight percent.

34. The pharmaceutical composition of claim 31, wherein the silver-containing compound present in the composition is at least about 1 weight percent.

35. The pharmaceutical composition of claim 31, wherein the silver-containing compound present in the composition is at least about 2 weight percent.

36. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound present in the composition is at least about 0.1 weight percent of a nanocrystalline silver compound.

37. The pharmaceutical composition of claim 36, wherein the silver-containing compound present in the composition is at least about 0.5 weight percent.

38. The pharmaceutical composition of claim 36, wherein the silver-containing compound present in the composition is at least about 0.75 weight percent.

39. The pharmaceutical composition of claim 36, wherein the silver-containing compound present in the composition is at least about 1 weight percent.

40. The pharmaceutical composition of claim 36, wherein the silver-containing compound present in the composition is at least about 2 weight percent.

41. The pharmaceutical composition of claim 1, wherein the silver-containing compound present in the composition is at least about 0.1 weight percent of an atomically disordered silver compound.

42. The pharmaceutical composition of claim 41, wherein the silver-containing compound present in the composition is at least about 0.5 weight percent.

43. The pharmaceutical composition of claim 41, wherein the silver-containing compound present in the composition is at least about 0.75 weight percent.

44. The pharmaceutical composition of claim 41, wherein the silver-containing compound present in the composition is at least about 1 weight percent.

45. The pharmaceutical composition of claim 41, wherein the silver-containing compound present in the composition is at least about 2 weight percent.